Recall of blood pressure drug losartan expanded
If you take blood pressure medicine, you'll want to double-check your bottle. Torrent Pharmaceuticals Ltd. has expanded its recall of losartan potassium and losartan potassium/hydrochlorothiazide tablets. (Source: CNN.com - Health)
Source: CNN.com - Health - April 20, 2019 Category: Consumer Health News Source Type: news

Recall Of Blood Pressure Drug Losartan Expanded
(CNN) — If you take blood pressure medicine, you’ll want to double-check your bottle. Torrent Pharmaceuticals Ltd. has expanded its recall of losartan potassium and losartan potassium/hydrochlorothiazide tablets. Tests found trace amounts of a potentially cancer-causing impurity called N-methylnitrosobutyric acid in some of these drugs. The company is recalling 36 additional lots, it said Thursday. A full list of recalled drugs is available on the US Food and Drug Administration website. Some of the recalled blood pressure medication (Image credit: FDA) The company hasn’t had any reports of users getting ...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - April 19, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News losartan Source Type: news

Torrent Recalls 104 More Lots of Tainted Losartan Tablets Torrent Recalls 104 More Lots of Tainted Losartan Tablets
The blood pressure tablets contain unacceptable levels of a potential carcinogen nitrosamine impurity that has prompted recalls by the company and other globally.News Alerts (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 19, 2019 Category: Cardiology Tags: Cardiology News Alert Source Type: news

Updated: Torrent Pharmaceuticals Limited Expands Voluntary Nationwide Recall of Losartan Potassium Tablets, USP and Losartan Potassium/Hydrochlorothiazide Tablets, USP
Torrent Pharmaceuticals Limited is expanding its recall for Losartan Potassium Tablets USP and Losartan Potassium/hydrochlorothiazide tablets, USP, to the consumer level due to the detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient (API) manufactured by Hetero Labs Limited. The Recall is expanded to include an additional 36 lots of Losartan potassium Tablets USP and 68 lots of Losartan Potassium/Hydrochlorothiazide Tablets, USP (Source: Food and Drug Administration)
Source: Food and Drug Administration - April 18, 2019 Category: Food Science Source Type: news

Defibrillator Hacking; Losartan Stay of Sentence; Guideline Evidence
(MedPage Today) -- Recent developments of interest in cardiovascular medicine (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - March 25, 2019 Category: Urology & Nephrology Source Type: news

Class 2 Medicines recall: Accord Healthcare Limited — Losartan potassium 50mg and 100mg film-coated tablets
Accord Healthcare Limited is recalling some batches of losartan potassium 50mg and 100mg film-coated tablets. (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - March 22, 2019 Category: Drugs & Pharmacology Source Type: news

FDA eases standards to avoid blood pressure drug shortages
The FDA announced that it will temporarily allow certain manufacturers to continue distributing losartan containing impurities slightly above the interim acceptable intake limit, in order to avoid shortages of certain blood pressure drugs. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - March 22, 2019 Category: Pharmaceuticals Source Type: news

Three more batches of blood pressure drugs are recalled by UK officials
UK Government agency the Medicines and Healthcare products Regulatory Agency today issued a warning about losartan pills made by the company Accord. (Source: the Mail online | Health)
Source: the Mail online | Health - March 21, 2019 Category: Consumer Health News Source Type: news

FDA Permits Temporary Distribution of Tainted Losartan FDA Permits Temporary Distribution of Tainted Losartan
To ensure patient access, certain losartan manufacturers can temporarily distribute the medication with higher levels of the probable carcinogen, the agency said.News Alerts (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - March 21, 2019 Category: Cardiology Tags: Cardiology News Alert Source Type: news

Morning Break: Safe-Enough Losartan;'Dirty' Kale; Governor's Pox Party
(MedPage Today) -- Health news and commentary from around the Web gathered by the MedPage Today staff (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - March 21, 2019 Category: American Health Source Type: news

Ripple Effect: Repackaged Losartan Recalled Due to Impurity Ripple Effect: Repackaged Losartan Recalled Due to Impurity
Legacy Pharmaceutical recalls 43 repackaged lots of losartan because of the presence of the probable carcinogen N-nitroso-N-methyl-4-aminobutyric acid (NMBA) in the active pharmaceutical ingredient.News Alerts (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - March 18, 2019 Category: Cardiology Tags: Cardiology News Alert Source Type: news

More blood pressure drugs recalled over potential cancer risk
Another 43 lots of the blood pressure and heart failure drug Losartan have been recalled over the detection of a possible carcinogen in the tablets. (Source: Health News - UPI.com)
Source: Health News - UPI.com - March 17, 2019 Category: Consumer Health News Source Type: news

Legacy Pharmaceutical Packaging, LLC Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP, 50mg Due to the Detection of Trace Amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA) Impurity found in the Active Pharmaceutical Ingredient (API)
Legacy Pharmaceutical Packaging, LLC is recalling 3 repackaged lots of Losartan Tablets USP 50mg to the consumer level. This recall was prompted due to Torrent Pharmaceuticals LTD issuing a Voluntary Nationwide Recall of Losartan Tablets, USP, due to the detection of trace amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA) a possible process impurity or contaminant in an active pharmaceutical ingredient, manufactured by Hetero Labs Limited, (API manufacturer). (Source: Food and Drug Administration)
Source: Food and Drug Administration - March 16, 2019 Category: Food Science Source Type: news

Legacy Pharmaceutical Packaging, LLC Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP, 25mg, 50mg, And 100mg Due to The Detection of Trace Amounts Of N-Nitroso N-Methyl 4-Amino Butyric Acid (NMBA) Impurity Found in The Active Pharmaceutical Ingredient (API)
Earth City, MO, Legacy Pharmaceutical Packaging, LLC is recalling 40 repackaged lots of Losartan Tablets USP 25mg, 50mg, and 100mg to the consumer level. This recall was prompted due to Camber Pharmaceuticals, Inc. issuing a Voluntary Nationwide Recall of Losartan Tablets, USP, due to the detection of trace amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA) a possible process impurity or contaminant in an active pharmaceutical ingredient, manufactured by Hetero Labs Limited, (API manufacturer). (Source: Food and Drug Administration)
Source: Food and Drug Administration - March 16, 2019 Category: Food Science Source Type: news

FDA Updates Sartan Recalls; Finds New Impurity FDA Updates Sartan Recalls; Finds New Impurity
Two companies recall losartan products owing to the presence of N-nitroso-N-methyl-4-aminobutyric acid (NMBA), the third type of nitrosamine impurity detected in angiotensin II receptor blockers.News Alerts (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - March 6, 2019 Category: Neurology Tags: Neurology & Neurosurgery News Alert Source Type: news

Blood pressure medication recall expands again to include losartan
A widespread recall of common blood pressure and heart failure medications has been expanded to include more drugs containing losartan. The recall is due to an "impurity" that is classified as a potential human carcinogen. (Source: CNN.com - Health)
Source: CNN.com - Health - March 4, 2019 Category: Consumer Health News Source Type: news

losartan and hydrochlorothiazide (Hyzaar)
Title: losartan and hydrochlorothiazide (Hyzaar)Category: MedicationsCreated: 3/12/2000 12:00:00 AMLast Editorial Review: 3/4/2019 12:00:00 AM (Source: MedicineNet High Blood Pressure General)
Source: MedicineNet High Blood Pressure General - March 4, 2019 Category: Cardiology Source Type: news

Blood pressure drug recall expands over third possible carcinogen
Drug companies expanded a recall of Losartan lots after detecting a third potentially cancer-causing impurity in blood pressure medication. (Source: Health News - UPI.com)
Source: Health News - UPI.com - March 2, 2019 Category: Consumer Health News Source Type: news

Blood Pressure Medication Recall Expands Again To Include Losartan
(CNN) — A widespread recall of common blood pressure and heart failure medications has been expanded to include more drugs containing losartan. The recall is due to an “impurity” that is classified as a potential human carcinogen. The impurity, N-Nitroso-N-methyl-4-aminobutyric acid or NMBA, is also classified as a known animal carcinogen, the US Food And Drug Administration noted in a news release about the recall Friday. Camber Pharmaceuticals Inc. voluntarily recalled 87 lots of losartan tablets in the United States on Thursday. The recalled tablets, made by Hetero Labs Ltd. In India and distributed by...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - March 1, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Consumer Health News FDA losartan Valsartan Source Type: news

Updated: Torrent Pharmaceuticals Limited Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP and Losartan Potassium /Hydrochlorothiazide Tablets, USP
Torrent Pharmaceuticals Limited is voluntarily recalling 60 lots of Losartan potassium tablets USP and 54 lots of Losartan potassium/ hydrochlorothiazide tablets, USP, to the consumer level due to the detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient (API) manufactured by Hetero Labs Limited. (Source: Food and Drug Administration)
Source: Food and Drug Administration - March 1, 2019 Category: Food Science Source Type: news

Another Day, Another ARB, Another Contaminant
(MedPage Today) -- Losartan lots from Indian drugmaker recalled for novel carcinogen (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - March 1, 2019 Category: American Health Source Type: news

Blood pressure drug Losartan recalled
Camber Pharmaceuticals is voluntarily recalling 87 lots of the blood pressure drug Losartan due to traces of a potential carcinogen. The affected products come in 25, 50 and 100 milligram doses. The company urges consumers to consult their doctor before stopping treatment. Since 2018, there have been at least 19 recalls of versions of the drug over cancer fears. (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - March 1, 2019 Category: Consumer Health News Source Type: news

FDA provides update on its ongoing investigation into ARB drug products; reports on finding of a new nitrosamine impurity in certain lots of losartan and product recall
FDA provides update on ongoing investigation into ARB drugs; new losartan recall announced (Source: Food and Drug Administration)
Source: Food and Drug Administration - March 1, 2019 Category: American Health Source Type: news

Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP, 25 mg, 50 mg and 100 mg Due to the Detection of Trace Amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA) Impurity found in the Active Pharmaceutical Ingredient (API)
Camber Pharmaceuticals, Inc. is recalling 87 lots of Losartan Tablets USP 25 mg, 50 mg, and 100 mg to consumer level. This recall was prompted due to the detection of trace amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA) a possible process impurity or contaminant in an active pharmaceutical ingredient, manufactured by Hetero Labs Limited, Unit – I (API manufacturer). (Source: Food and Drug Administration)
Source: Food and Drug Administration - March 1, 2019 Category: Food Science Source Type: news

Another Drug Company Recalls Tainted Losartan Another Drug Company Recalls Tainted Losartan
Macleods Pharmaceuticals Limited is voluntarily recalling one lot of losartan potassium and hydrochlorothiazide combination tablets owing to the presence of a probable carcinogen.News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 27, 2019 Category: Consumer Health News Tags: Cardiology News Alert Source Type: news

Macleods Pharmaceuticals Limited Issues Voluntary Nationwide Consumer Level Recall of One Lot (BLM 715A) of Losartan Potassium/Hydrochlorothiazide Combination Tablets 100mg/25mg Due to detection of NDEA (N-Nitrosodiethylamine) Impurity
Macleods Pharmaceuticals Limited is voluntarily recalling one lot of Losartan Potassium/Hydrochlorothiazide combination tablets 100mg/25mg to the consumer level due to the detection of trace amounts of an unexpected impurity (NDEA) found in finished product manufactured with active pharmaceutical ingredient made by Hetero Labs Limited. (Source: Food and Drug Administration)
Source: Food and Drug Administration - February 25, 2019 Category: Food Science Source Type: news

Commonly-prescribed blood-pressure drug may combat PTSD
A study by the University of Electronic Science and Technology of China found the hypertension drug losartan - also known by its brand name Cozaar - helps people sweat less when faced with a fear. (Source: the Mail online | Health)
Source: the Mail online | Health - February 19, 2019 Category: Consumer Health News Source Type: news

Cancer Fears Have Triggered Blood Pressure Drug Recalls for Months. Now Patients Are ‘Leery’
Cynthia Brown had been taking the drug valsartan for about two years when she learned last August that it had been recalled over fears of potential carcinogen contamination. Brown, a writer and patient advocate living near Cincinnati, had been prescribed valsartan to control shortness of breath related to primary pulmonary hypertension, but suddenly she had a whole new concern: cancer. “I’ve always been very conscientious about my health. I never dreamed I’d be on all these medications, and I’m real funny about what I take,” Brown, 65, says. “Valsartan has made me leery of all medication...
Source: TIME: Health - January 29, 2019 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized Drugs healthytime Source Type: news

Torrent Recalls Six More Lots of Tainted Losartan Tablets Torrent Recalls Six More Lots of Tainted Losartan Tablets
The company has recalled a total of 16 lots of losartan potassium and hydrochlorothiazide combination tablets because of the presence of a probable carcinogen.News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 24, 2019 Category: Consumer Health News Tags: Cardiology News Alert Source Type: news

UPDATED: Torrent Pharmaceuticals Limited Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP and Losartan Potassium and Hydrochlorothiazide Tablets, USP
Torrent Pharmaceuticals Limited is expanding its voluntary recall from 10 lots of Losartan potassium tablets USP to include 6 lots of Losartan potassium and hydrochlorothiazide tablets, USP, to the consumer level due to the detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient (API) manufactured by Hetero Labs Limited. (Source: Food and Drug Administration)
Source: Food and Drug Administration - January 22, 2019 Category: Food Science Source Type: news

Antihypertension drug losartan may improve treatment of ovarian cancer
(Massachusetts General Hospital) A new study from a Massachusetts General Hospital research team has found that the hypertension drug losartan, which targets the angiotensin signaling pathway, may improve the effectiveness of chemotherapy agents used to treat ovarian cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 15, 2019 Category: Cancer & Oncology Source Type: news

Heart Drug Recall Expanded Again
(CNN) — The recall of popular heart drugs has expanded yet again. The US Food and Drug Administration said Thursday that Torrent Pharmaceuticals has added eight additional lots of losartan potassium tablets to its recall list. Losartan potassium is a drug used to control high blood pressure. It is also used to treat kidney disease in patients with diabetes. This recall includes 30-, 90- and 1,000-count bottles of 100-milligram tablets; 30-, 90- and 1,000-count bottles of 50-milligram tablets; and 90-count bottles of 25-milligram tablets. Torrent is recalling only these particular losartan potassium tablets. Tests fou...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - January 4, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News CNN Recall Valsartan Source Type: news

Heart drug recall expanded again
The recall of heart drugs has expanded again to include Torrent Pharmaceuticals losartan potassium and Aurobindo Pharma USA Inc. drugs containing valsartan. (Source: CNN.com - Health)
Source: CNN.com - Health - January 4, 2019 Category: Consumer Health News Source Type: news

Torrent Pharmaceuticals Limited Expands Voluntary Nationwide Recall of Losartan Potassium Tablets, USP
Torrent Pharmaceuticals Limited is expanding its voluntary recall from 2 lots of Losartan potassium tablets USP to a total of 10 lots, to the consumer level due to the detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient (API) manufactured by Hetero Labs Limited. Torrent is only recalling lots of losartan-containing products that contain N-nitrosodiethylamine (NDEA) above the acceptable daily intake levels released by the FDA. (Source: Food and Drug Administration)
Source: Food and Drug Administration - January 3, 2019 Category: Food Science Source Type: news

Blood pressure medication recalled after cancer-causing chemical found
FDA announces that Torrent Pharmaceuticals Limited is voluntarily recalling two lots of Losartan potassium tablets (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - December 23, 2018 Category: Consumer Health News Source Type: news

Torrent Pharma Recalls Two Lots of Tainted Losartan Tablets Torrent Pharma Recalls Two Lots of Tainted Losartan Tablets
In the next chapter of the ongoing tainted-ARB saga, the recall covers certain lots of losartan potassium tablets found to contain what were called trace amounts of the probable carcinogen NDEA.News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 21, 2018 Category: Consumer Health News Tags: Cardiology News Source Type: news

Torrent Pharmaceuticals Limited Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP
Torrent Pharmaceuticals Limited is voluntarily recalling 2 lots of Losartan potassium tablets, USP to the consumer level due to the detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient (API) manufactured by Hetero Labs Limited. The impurity detected in the API is N-nitrosodiethylamine (NDEA), which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probable human carcinogen as per International Agency for Research on Cancer (IARC) classification. (Source: Food and Drug Administration)
Source: Food and Drug Administration - December 20, 2018 Category: Food Science Source Type: news

Medical News Today: Losartan potassium: Uses and warnings
This article provides an overview of the benefits, effectiveness, side effects, and warnings associated with losartan potassium. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 18, 2018 Category: Consumer Health News Tags: Hypertension Source Type: news

Another Tainted'Sartan' Recalled for Impurity Another Tainted'Sartan' Recalled for Impurity
Sandoz, along with FDA, has recalled one lot of losartan potassium hydrochlorothiazide tablets because of the presence of the probable human carcinogen NDEA.News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 16, 2018 Category: Consumer Health News Tags: Cardiology News Alert Source Type: news

Losartan Latest BP Drug Recalled for Contamination
NDEA is found naturally in certain foods, drinking water, air pollution, and industrial processes, and it may cause cancer, according to the International Agency for Research on Cancer. (Source: WebMD Health)
Source: WebMD Health - November 13, 2018 Category: Consumer Health News Source Type: news

3rd blood pressure drug, losartan, recalled in recent weeks over impurity
For the third time in recent weeks, a blood pressure medication has been recalled because it may have been contaminated with an agent linked to cancer. (Source: Health News - UPI.com)
Source: Health News - UPI.com - November 13, 2018 Category: Consumer Health News Source Type: news

Blood Pressure Drug Recall Expands Again; Meds May Be Tainted With Cancer-Causing Chemical
(CNN) — The US Food and Drug Administration says another heart medicine is being voluntarily recalled after tests showed that it was tainted with a potential cancer-causing chemical. The recall includes one lot of Sandoz’s losartan potassium hydrochlorothiazide 100 milligram/25 milligram tablets with the lot number JB8912. Patients use these drugs to keep their high blood pressure in check. The drug is being recalled because the active ingredient has tested positive for N-Nitrosodiethylamine or NDEA, a suspected human and animal carcinogen that is used in gasoline as a stabilizer for industry materials and as a...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - November 12, 2018 Category: Consumer Health News Authors: Health – CBS Boston Tags: Consumer Health News Local TV Valsartan Source Type: news

Sandoz recalls China-made blood pressure drug
Novartis said its Sandoz division is recalling one lot of losartan tablets after finding traces of a probable carcinogen in the blood pressure drug. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - November 12, 2018 Category: Pharmaceuticals Source Type: news

Sandoz Inc. Issues Voluntary Nationwide Recall of One Lot of Losartan Potassium and Hydrochlorothiazide Due to the Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Found in the Active Pharmaceutical Ingredient (API)
Sandoz Inc. is voluntarily recalling one lot of Losartan Potassium Hydrochlorothiazide Tablets, USP 100mg/25mg to the consumer level. This product is being recalled due to the trace amount of an impurity, N-nitrosodiethylamine (NDEA) contained in the API Losartan, USP manufactured by Zhejiang Huahai Pharmaceutical Co. Ltd. Sandoz Inc. Losartan Potassium Hydrochlorothiazide product is manufactured by Lek Pharmaceuticals dd, Ljubljana, Slovenia. This impurity, which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, has been classified as a probable human carcinoge...
Source: Food and Drug Administration - November 9, 2018 Category: Food Science Source Type: news

Novartis division Sandoz recalls one lot of blood pressure drug
Novartis said on Thursday its Sandoz division was recalling one lot of losartan tablets after finding traces of a probable carcinogen in the blood pressure drug. (Source: Reuters: Health)
Source: Reuters: Health - November 9, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Black cumin prevents kidney damage
(Natural News) The extract of black cumin (Nigella sativa) can help treat kidney damage induced by unilateral ureteral obstruction (UUO). This was what a study, published in the journal Phytochemical Research, found. The researchers administered an intraperitoneal injection of losartan (15 mg/kg), captopril (30 mg/kg), 200 mg/kg of N. sativa extract (NS), and 400 mg/kg NS... (Source: NaturalNews.com)
Source: NaturalNews.com - October 26, 2018 Category: Consumer Health News Source Type: news

Losartan vs. Valsartan (Differences between Side Effects and Uses)
Title: Losartan vs. Valsartan (Differences between Side Effects and Uses)Category: MedicationsCreated: 9/21/2018 12:00:00 AMLast Editorial Review: 9/21/2018 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - September 21, 2018 Category: Drugs & Pharmacology Source Type: news

Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Montelukast Tablets USP, 10mg 30Ct. due to Product/Label Mix-Up
Camber Pharmaceuticals, Inc. is voluntarily recalling one single lot of Montelukast Sodium Tablets, USP 10mg, to the consumer level. This recall of one batch of Montelukast Sodium Tablets, USP 10mg, lot# MON17384 Exp. 12/31/2019, was prompted because a complaint of a sealed bottle labeled as Montelukast 10mg 30 ct found to contain 90 tablets of Losartan Potassium Tablets, USP 50mg (Source: Food and Drug Administration)
Source: Food and Drug Administration - September 7, 2018 Category: Food Science Source Type: news

Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Montelukast Tablets USP, 10mg 30Ct. due to product/label mix-up
PISCATAWAY, N.J., Sept. 6, 2018 -- (Healthcare Sales & Marketing Network) -- Camber Pharmaceuticals, Inc. is voluntarily recalling one single lot of Montelukast Sodium Tablets, USP 10mg, to the consumer level. This recall of one batch of Montelukast Sodiu... Biopharmaceuticals, FDA, Product Recall Camber Pharmaceuticals, Montelukast, Losartan (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 6, 2018 Category: Pharmaceuticals Source Type: news

Label Mix-Up Prompts Montelukast Recall Label Mix-Up Prompts Montelukast Recall
Pill bottles that are labeled as montelukast sodium tablets but actually contain the antihypertensive losartan potassium are being recalled.News Alerts (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - August 31, 2018 Category: Internal Medicine Tags: Pulmonary Medicine News Alert Source Type: news